Touitou I, Rittore C, Philibert L, Yagüe J, Shinar Y, Aksentijevich I
Unité Médicale des Maladies Auto-Inflammatoires, CHU Montpellier, Montpellier, France.
Eur J Hum Genet. 2009 Jul;17(7):890-6. doi: 10.1038/ejhg.2008.253. Epub 2009 Jan 28.
Hereditary recurrent fevers (HRF) are rare diseases caused by molecular defects in genes involved in the regulation of innate immunity. Sixty-seven international laboratories participated in an external quality assessment (EQA) scheme, which was developed to appraise the accuracy of genetic testing. Reports were evaluated for the 12 items recommended by the OECD (Organisation for Economic Co-Operation and Development) guidelines for molecular diagnostics. The best documented items were the name of the gene, the biologist, or the patient, whereas information on the test and screening limits, and clinical interpretation of the disease inheritance were scarcely provided. The mutation nomenclature was incomplete in about 70% of the cases. In the first 2 years of EQA, we identified almost 30% genotyping error rate, which decreased markedly in the last year. The combined performance on the basis of the correct identification of all genotypes by a given laboratory in all the 3 years was only 40%, showing a critical need for improvement.
遗传性周期性发热(HRF)是由参与先天性免疫调节的基因分子缺陷引起的罕见疾病。67个国际实验室参与了一项外部质量评估(EQA)计划,该计划旨在评估基因检测的准确性。根据经济合作与发展组织(OECD)分子诊断指南推荐的12项内容对报告进行了评估。记录最完善的项目是基因名称、生物学家或患者,而关于检测和筛查限度以及疾病遗传临床解释的信息则很少提供。在大约70%的病例中,突变命名法不完整。在EQA的前两年,我们发现基因分型错误率近30%,而在最后一年显著下降。基于某一实验室在所有三年中正确识别所有基因型的综合表现仅为40%,这表明迫切需要改进。